Literature DB >> 32908842

Hydroxychloroquine in a G6PD-Deficient Patient with COVID-19 Complicated by Haemolytic Anaemia: Culprit or Innocent Bystander?

François Mastroianni1, Vincent Colombie1, Geraldine Claes2, Axelle Gilles2, Frédéric Vandergheynst3, Sammy Place1.   

Abstract

Hydroxychloroquine has been used worldwide as a first-line treatment for patients hospitalized with COVID-19. Little is known about COVID-19 and its effects on patients with congenital red blood cell disorders. We report a case of haemolytic anaemia in a 32-year-old patient and a fortuitous highlighting of G6PD deficiency. We reviewed the literature to assess the risk of hydroxychloroquine use in this context. LEARNING POINTS: A rapid drop in haemoglobin in COVID-19 patients should alert physicians to test for haemolytic anaemia and enzymopathies.Our review of the literature shows that use of hydroxychloroquine is safe in G6PD-deficient patients. © EFIM 2020.

Entities:  

Keywords:  COVID-19; G6PD deficiency; Haemolytic anaemia; SARS-CoV-2

Year:  2020        PMID： 32908842      PMCID： PMC7473690          DOI： 10.12890/2020_001875

Source DB:  PubMed          Journal:  Eur J Case Rep Intern Med        ISSN： 2284-2594


  11 in total

1.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

2.  Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6PDH-Deficient Patients.

Authors:  Samya Mohammad; Megan E B Clowse; Amanda M Eudy; Lisa G Criscione-Schreiber
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-02-09       Impact factor: 4.794

Review 3.  Glucose-6-phosphate dehydrogenase deficiency.

Authors:  M D Cappellini; G Fiorelli
Journal:  Lancet       Date:  2008-01-05       Impact factor: 79.321

4.  Glucose-6-phosphate dehydrogenase deficiency enhances enterovirus 71 infection.

Authors:  Hung-Yao Ho; Mei-Ling Cheng; Shiue-Fen Weng; Lo Chang; Tsun-Tsun Yeh; Shin-Ru Shih; Daniel Tsun-Yee Chiu
Journal:  J Gen Virol       Date:  2008-09       Impact factor: 3.891

Review 5.  Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review.

Authors:  Ilan Youngster; Lidia Arcavi; Renata Schechmaster; Yulia Akayzen; Hen Popliski; Janna Shimonov; Svetlana Beig; Matitiahu Berkovitch
Journal:  Drug Saf       Date:  2010-09-01       Impact factor: 5.228

6.  COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency.

Authors:  Yan Beauverd; Yannick Adam; Benjamin Assouline; Kaveh Samii
Journal:  Eur J Haematol       Date:  2020-05-07       Impact factor: 2.997

7.  A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine.

Authors:  E Maillart; S Leemans; H Van Noten; T Vandergraesen; B Mahadeb; M T Salaouatchi; D De Bels; P Clevenbergh
Journal:  Infect Dis (Lond)       Date:  2020-06-04

8.  Doubtful precipitation of hemolysis by hydroxychloroquine in glucose-6-phosphate dehydrogenase-deficient patient with COVID-19 infection.

Authors:  T P Afra; Ram Vasudevan Nampoothiri; Muhammed Razmi T
Journal:  Eur J Haematol       Date:  2020-07-02       Impact factor: 3.674

9.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.

Authors:  Philippe Gautret; Jean-Christophe Lagier; Philippe Parola; Van Thuan Hoang; Line Meddeb; Morgane Mailhe; Barbara Doudier; Johan Courjon; Valérie Giordanengo; Vera Esteves Vieira; Hervé Tissot Dupont; Stéphane Honoré; Philippe Colson; Eric Chabrière; Bernard La Scola; Jean-Marc Rolain; Philippe Brouqui; Didier Raoult
Journal:  Int J Antimicrob Agents       Date:  2020-03-20       Impact factor: 5.283

10.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

Authors:  Xueting Yao; Fei Ye; Miao Zhang; Cheng Cui; Baoying Huang; Peihua Niu; Xu Liu; Li Zhao; Erdan Dong; Chunli Song; Siyan Zhan; Roujian Lu; Haiyan Li; Wenjie Tan; Dongyang Liu
Journal:  Clin Infect Dis       Date:  2020-07-28       Impact factor: 9.079
View more
  6 in total

Review 1.  Treatment strategies for glucose-6-phosphate dehydrogenase deficiency: past and future perspectives.

Authors:  Adriana A Garcia; Ana Koperniku; Julio C B Ferreira; Daria Mochly-Rosen
Journal:  Trends Pharmacol Sci       Date:  2021-08-10       Impact factor: 17.638

2.  The Possible Role of Glucose-6-Phosphate Dehydrogenase in the SARS-CoV-2 Infection.

Authors:  Israel Pérez-Torres; María Elena Soto; Verónica Guarner-Lans; Linaloe Manzano-Pech; Elizabeth Soria-Castro
Journal:  Cells       Date:  2022-06-21       Impact factor: 7.666

Review 3.  Glucose-6-phosphate dehydrogenase deficiency and hydroxychloroquine in the COVID-19 era: a mini review.

Authors:  Maria Elisabetta Onori; Claudio Ricciardi Tenore; Andrea Urbani; Angelo Minucci
Journal:  Mol Biol Rep       Date:  2021-02-23       Impact factor: 2.316

4.  Occurrence of Methemoglobinemia due to COVID-19: A Case Report.

Authors:  Ohoud F Kashari; Salihah A Alsamiri; Fatimah M Zabbani; Dania I Musalli; Ahmed M Ibrahim
Journal:  Cureus       Date:  2022-03-14

5.  Hydroxychloroquine Therapy Led to the Diagnosis of Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency in an Elderly Patient with COVID-19 Involvement: A Case Report and Review of the Literature.

Authors:  Razieh Taghizadeh-Sarvestani; Hamid Reihani; Ali Ghanei-Shahmirzadi; Alireza Keshtkar; Parsa Yazdanpanahi
Journal:  Case Rep Med       Date:  2022-10-03

Review 6.  Pharmacogenetics Approach for the Improvement of COVID-19 Treatment.

Authors:  Ingrid Fricke-Galindo; Ramcés Falfán-Valencia
Journal:  Viruses       Date:  2021-03-05       Impact factor: 5.048
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.